Opendata, web and dolomites

ROADMAP

Real world Outcomes across the AD spectrum for better care: Multimodal data Access Platform - Sofia ref.: 116020

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ROADMAP project word cloud

Explore the words cloud of the ROADMAP project. It provides you a very rough idea of what is the project "ROADMAP" about.

expertise    outstanding    progression    packages    costing    platform    strategy    solutions    roadmap    risk    scalable    communication    connections    implications    consist    pursue    levels    ad    emif    health    parallel    models    companies    synergies    big    modal    dataset    transferable    strategies    informatics    markers    contribution    piloting    sources    integration    characterisation    direct    industry    professionals    hta    elsi    engaging    dpuk    foundation    focussing    diverse    outcomes    pool    data    datasets    collected    leverage    framework    stakeholder    epidemiologic    routinely    brings    providers    regulators    biomedical    software    rwe    economics    outcome    definition    patients    standards    guidelines    carers    sourcing    actionable    experts    deepen    traction    epad    interpretation    patient    combining    validate    national    consensual    world    social    classification    groups    service    tools    he    handling    imi2    disease    ethical   

Project "ROADMAP" data sheet

The following table provides information about the project.

Coordinator
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD 

Organization address
address: WELLINGTON SQUARE UNIVERSITY OFFICES
city: OXFORD
postcode: OX1 2JD
website: www.ox.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://roadmap-alzheimer.org/
 Total cost 8˙210˙381 €
 EC max contribution 3˙998˙250 € (49%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2015-06-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2016
 Duration (year-month-day) from 2016-11-01   to  2018-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UK (OXFORD) coordinator 1˙073˙500.00
2    NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE UK (MANCHESTER) participant 292˙500.00
3    THE UNIVERSITY OF EDINBURGH UK (EDINBURGH) participant 291˙000.00
4    UNIVERSITEIT MAASTRICHT NL (MAASTRICHT) participant 291˙000.00
5    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 252˙000.00
6    GOETEBORGS UNIVERSITET SE (GOETEBORG) participant 250˙500.00
7    AARHUS UNIVERSITET DK (AARHUS C) participant 212˙250.00
8    FUNDACIO INSTITUT UNIVERSITARI PERA LA RECERCA A L'ATENCIO PRIMARIA DE SALUT JORDI GOL I GURINA ES (BARCELONA) participant 212˙250.00
9    SYNAPSE RESEARCH MANAGEMENT PARTNERS SL ES (MADRID) participant 188˙750.00
10    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM NL (ROTTERDAM) participant 181˙000.00
11    LONDON SCHOOL OF ECONOMICS AND POLITICAL SCIENCE UK (LONDON) participant 178˙500.00
12    ALZHEIMER EUROPE LU (LUXEMBOURG) participant 176˙000.00
13    AGENTSCHAP COLLEGE TER BEOORDELING VAN GENEESMIDDELEN NL (UTRECHT) participant 122˙000.00
14    IXICO TECHNOLOGIES LIMITED UK (LONDON) participant 117˙000.00
15    ACADEMISCH ZIEKENHUIS LEIDEN NL (LEIDEN) participant 110˙000.00
16    RIJKSUNIVERSITEIT GRONINGEN NL (GRONINGEN) participant 50˙000.00
17    AC IMMUNE SA CH (Lausanne) participant 0.00
18    BIOGEN IDEC LIMITED UK (MAIDENHEAD) participant 0.00
19    CHU HOPITAUX DE BORDEAUX FR (TALENCE) participant 0.00
20    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
21    F. HOFFMANN-LA ROCHE AG CH (BASEL) participant 0.00
22    GE HEALTHCARE LIMITED UK (LITTLE CHALFONT) participant 0.00
23    H. LUNDBECK AS DK (VALBY) participant 0.00
24    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
25    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
26    TAKEDA DEVELOPMENT CENTRE EUROPE LTD UK (LONDON) participant 0.00

Map

 Project objective

The aim of ROADMAP is to provide the foundation for a Europe-wide real world evidence (RWE) platform in AD by piloting multi-modal data integration tools and engaging with all key stakeholder groups for consensual definition of patient outcomes, tools and methods that are actionable and relevant. ROADMAP will leverage best practice and exploit synergies with other projects and initiatives at the national and European levels in pursue of scalable and transferable solutions for dataset characterisation, outcome classification, data standards, data sourcing, software application and guidelines on the handling and interpretation of RWE data. In parallel, the project will deepen understanding of the ethical, legal and social implications (ELSI) and health economics (HE) impact of a RWE approach for a meaningful contribution to the Big Data for Better Outcomes programme in IMI2.

The ROADMAP programme will consist of 8 integrated work packages by which the Consortium will work to (1) identify relevant AD outcomes and progression markers; (2) identify and pool AD-related RWE across data sources; (3) develop and validate disease progression models combining diverse datasets and strategies; (4) develop risk/value-based costing and health economics models for HTA/regulators, service providers, industry and carers; (5) establish stakeholder-based guidelines for RWE; (6) develop a communication strategy focussing on the needs of patients and professionals; (7) develop an ELSI framework for the development and application of RWE in AD.

The ROADMAP consortium brings together outstanding expertise, experience and traction in the field, including many of Europe’s top institutions, authorities, companies, experts in AD, biomedical informatics and analysis of epidemiologic and routinely collected health data sources, providing direct connections to key initiatives such as DPUK, EMIF, EPAD and others.

 Deliverables

List of deliverables.
Final report on dissemination activities (including impact measures) and project tools developed Documents, reports 2019-10-08 14:19:00
Interim Report on dissemination activities and communication strategy update Documents, reports 2019-10-08 14:19:01
Update on potential data sources with RWE data in Europe Documents, reports 2019-10-08 14:18:53
Initial set of communication tools Documents, reports 2019-10-08 14:19:01
First list of priority Real World Evidence relevant outcomes for AD Documents, reports 2019-10-08 14:19:04
First report on proof of concept technical solutions for RWE data harmonisation and integration Documents, reports 2019-10-08 14:18:47
Project website Websites, patent fillings, videos etc. 2019-10-08 14:19:01
Final report on requirements for ELSI framework for a RWE approach in AD Documents, reports 2019-10-08 14:19:02
Landscaping paper on ethics of outcome prioritisation in AD treatment Documents, reports 2019-10-08 14:19:04
Structured review of existing C-E models and evidence Documents, reports 2019-10-08 14:18:59
Final report on proof of concept technical solutions for RWE data harmonisation and integration Documents, reports 2019-10-08 14:18:59
Brief on findings of ELSI focus groups for RWE approach to AD Documents, reports 2019-10-08 14:19:02
Catalogue of RWE relevant AD models and simplistic disease stage framework Documents, reports 2019-10-08 14:19:02
Report of systematic review of published an unpublished data identifying important and relevant outcomes in AD and criteria for disease progression Documents, reports 2019-10-08 14:19:04
Overview of potential data sources with RWE data in Europe Documents, reports 2019-10-08 14:18:48
Summary of gaps between data requirements and currently available data Documents, reports 2019-10-08 14:18:40
Interim report on the EXAG activities and outputs Documents, reports 2019-10-08 14:18:59
Review of ELSI issues in RWE approach Documents, reports 2019-10-08 14:19:01
Report on results from ‘hypothesis-free’ disease trajectory analyses Documents, reports 2019-10-08 14:18:59
RWE progression marker and outcome classification matrix for AD Documents, reports 2019-10-08 14:18:36
Recommendations for the development/interpretation of RWE AD models Documents, reports 2019-07-25 18:35:48
Mapping algorithms from real world outcomes to preference-based measures Documents, reports 2019-07-25 18:35:48
Selection of appropriate disease models for validation Documents, reports 2019-07-25 18:35:48
Proof of concept AD C-E model Documents, reports 2019-07-25 18:35:48
Guidelines for combining RCT, cohort, and EHR-based data for RWE in AD Documents, reports 2019-07-25 18:35:48
Report on results from pilot model validation exercises Documents, reports 2019-07-25 18:35:48
Guiding principles and recommendations for the development and incorporation of RWE into clinical and market access development plans for AD Documents, reports 2019-07-25 18:35:49
Guidelines for use of smart devices as a measure of RWE Documents, reports 2019-07-25 18:35:48
Paper on the regulatory and HTA experience with AD-approved products Documents, reports 2019-07-25 18:35:48
Report on results from analysis of pharmacological interventions Documents, reports 2019-07-25 18:35:49

Take a look to the deliverables list in detail:  detailed list of ROADMAP deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Szócska, Miklós and Jayawardana, Sahan and Smand, Carin and Salimullah, Tayyab and Reed, Catherine and Hanif, Shahid
Big data for better outcomes: supporting health care system transformation in Europe
published pages: , ISSN: 1356-1030, DOI:
EUROHEALTH 2019-07-25
2018 Jacoline C. Bouvy, Pall Jonsson, Diana O’Rourke, Antonella Santuccione Chadha, Niklas Hedberg, Amr Makady, Entela Xoxi, Christine Gispen-de Wied, Anja Schiel, Raj Long, John Gallacher
Regulatory and Health Technology Assessment Considerations for Disease-Modifying Drugs in Alzheimer’s Disease
published pages: 1085-1090, ISSN: 1172-7047, DOI: 10.1007/s40263-018-0581-x
CNS Drugs 32/12 2019-07-25
2019 Claire Tochel, Michael Smith, Helen Baldwin, Anders Gustavsson, Amanda Ly, Christin Bexelius, Mia Nelson, Christophe Bintener, Enrico Fantoni, Josep Garre-Olmo, Olin Janssen, Christoph Jindra, Isabella F. Jørgensen, Alex McKeown, Buket Öztürk, Anna Ponjoan, Michele H. Potashman, Catherine Reed, Emilse Roncancio-Diaz, Stephanie Vos, Cathie Sudlow
What outcomes are important to patients with mild cognitive impairment or Alzheimer\'s disease, their caregivers, and health-care professionals? A systematic review
published pages: 231-247, ISSN: 2352-8729, DOI: 10.1016/j.dadm.2018.12.003
Alzheimer\'s & Dementia: Diagnosis, Assessment & Disease Monitoring 11 2019-07-25
2019 Zuzanna Angehrn, Clementine Nordon, Andrew Turner, Dianne Gove, Helene Karcher, Alexander Keenan, Monika Neumann, Jelena Sostar, Frederic de Reydet de Vulpillieres
Ethical and social implications of using predictive modeling for Alzheimer’s disease prevention: a systematic literature review protocol
published pages: e026468, ISSN: 2044-6055, DOI: 10.1136/bmjopen-2018-026468
BMJ Open 9/3 2019-07-25
2019 Anna Ponjoan, Josep Garre-Olmo, Jordi Blanch, Ester Fages, Lia Alves-Cabratosa, Ruth Martí-Lluch, Marc Comas-Cufí, Dídac Parramon, María Garcia-Gil, Rafel Ramos

Epidemiology of dementia: prevalence and incidence estimates using validated electronic health records from primary care


published pages: 217-228, ISSN: 1179-1349, DOI: 10.2147/clep.s186590
Clinical Epidemiology Volume 11 2019-07-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ROADMAP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ROADMAP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

RespiriNTM (2019)

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More